Heart failure, peripheral artery disease, and dapagliflozin: a patient-level meta-analysis of DAPA-HF and DELIVER.
Jawad Haider ButtToru KondoMingming YangPardeep S JhundKieran F DochertyMuthiah VaduganathanBrian L ClaggettAdrian F HernandezCarolyn Su Ping LamSilvio E InzucchiFelipe A MartinezRudolf A de BoerMikhail N KosiborodAkshay S DesaiLars KøberPiotr PonikowskiMarc S SabatineSanjiv J ShahNatalia ZaozerskaUlrica WilderängOlof F BengtssonScott D SolomonJohn Joseph Valentine McMurrayPublished in: European heart journal (2023)
The risk of worsening HF or cardiovascular death was higher in patients with PAD, as was the risk of amputation. The benefits of dapagliflozin were consistent in patients with and without PAD, and dapagliflozin did not increase the risk of amputation.